Endothelial cells in the bone marrow of patients with multiple myeloma

Angelo Vacca, Roberto Ria, Fabrizio Semeraro, Francesca Merchionne, Mauro Coluccia, Angela Boccarelli, Claudio Scavelli, Beatrice Nico, Angela Gernone, Feliciana Battelli, Antonio Tabilio, Diego Guidolin, Maria Teresa Petrucci, Domenico Ribatti, Franco Dammacco

Research output: Contribution to journalArticle

Abstract

Endothelial cells (EC) were extracted through a lectin-based method from bone marrow of 57 patients with active multiple myeloma (MM) and compared with their healthy quiescent counterpart, human umbilical vein EC (HUVEC). MMECs exhibit specific antigens that indicate ongoing angiogenesis and embryo vasculogenesis; solid intercellular connections, hence stability of MM neovessels; and frequent interactions with plasma cells, hence tumor dissemination. They show heterogeneous antigen expression, hence existence of subsets. Their main genetic markers are indicative of a vascular phase. They show intrinsic angiogenic ability, because they rapidly form a capillary network in vitro, and extrinsic ability, because they generate numerous new vessels in vivo. They vividly secrete growth and invasive factors for plasma cells. They signal through kinases mandatory for development of neovascularization. Ultrastructurally, they are abnormal and show metabolic activation, like tumor ECs. Thalidomide heavily interferes with their functions. Vasculogenesis and angiogenesis might contribute to the MM vascular tree and progression, in the form of growth, invasion, and dissemination. In view of the heterogeneity of the antigenic phenotype of MMECs, a mixture (or a sequence) of antiangiogenic agents coupled with thalidomide would seem plausible for the biologic management of MM.

Original languageEnglish
Pages (from-to)3340-3348
Number of pages9
JournalBlood
Volume102
Issue number9
DOIs
Publication statusPublished - Nov 1 2003

Fingerprint

Thalidomide
Endothelial cells
Multiple Myeloma
Tumors
Bone
Endothelial Cells
Bone Marrow
Plasmas
Antigens
Angiogenesis Inhibitors
Beam plasma interactions
Lectins
Blood Vessels
Phosphotransferases
Chemical activation
Plasmacytoma
Human Umbilical Vein Endothelial Cells
Plasma Cells
Genetic Markers
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Hematology

Cite this

Vacca, A., Ria, R., Semeraro, F., Merchionne, F., Coluccia, M., Boccarelli, A., ... Dammacco, F. (2003). Endothelial cells in the bone marrow of patients with multiple myeloma. Blood, 102(9), 3340-3348. https://doi.org/10.1182/blood-2003-04-1338

Endothelial cells in the bone marrow of patients with multiple myeloma. / Vacca, Angelo; Ria, Roberto; Semeraro, Fabrizio; Merchionne, Francesca; Coluccia, Mauro; Boccarelli, Angela; Scavelli, Claudio; Nico, Beatrice; Gernone, Angela; Battelli, Feliciana; Tabilio, Antonio; Guidolin, Diego; Petrucci, Maria Teresa; Ribatti, Domenico; Dammacco, Franco.

In: Blood, Vol. 102, No. 9, 01.11.2003, p. 3340-3348.

Research output: Contribution to journalArticle

Vacca, A, Ria, R, Semeraro, F, Merchionne, F, Coluccia, M, Boccarelli, A, Scavelli, C, Nico, B, Gernone, A, Battelli, F, Tabilio, A, Guidolin, D, Petrucci, MT, Ribatti, D & Dammacco, F 2003, 'Endothelial cells in the bone marrow of patients with multiple myeloma', Blood, vol. 102, no. 9, pp. 3340-3348. https://doi.org/10.1182/blood-2003-04-1338
Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003 Nov 1;102(9):3340-3348. https://doi.org/10.1182/blood-2003-04-1338
Vacca, Angelo ; Ria, Roberto ; Semeraro, Fabrizio ; Merchionne, Francesca ; Coluccia, Mauro ; Boccarelli, Angela ; Scavelli, Claudio ; Nico, Beatrice ; Gernone, Angela ; Battelli, Feliciana ; Tabilio, Antonio ; Guidolin, Diego ; Petrucci, Maria Teresa ; Ribatti, Domenico ; Dammacco, Franco. / Endothelial cells in the bone marrow of patients with multiple myeloma. In: Blood. 2003 ; Vol. 102, No. 9. pp. 3340-3348.
@article{1c84dd78798848b5883af0f0beb37e9e,
title = "Endothelial cells in the bone marrow of patients with multiple myeloma",
abstract = "Endothelial cells (EC) were extracted through a lectin-based method from bone marrow of 57 patients with active multiple myeloma (MM) and compared with their healthy quiescent counterpart, human umbilical vein EC (HUVEC). MMECs exhibit specific antigens that indicate ongoing angiogenesis and embryo vasculogenesis; solid intercellular connections, hence stability of MM neovessels; and frequent interactions with plasma cells, hence tumor dissemination. They show heterogeneous antigen expression, hence existence of subsets. Their main genetic markers are indicative of a vascular phase. They show intrinsic angiogenic ability, because they rapidly form a capillary network in vitro, and extrinsic ability, because they generate numerous new vessels in vivo. They vividly secrete growth and invasive factors for plasma cells. They signal through kinases mandatory for development of neovascularization. Ultrastructurally, they are abnormal and show metabolic activation, like tumor ECs. Thalidomide heavily interferes with their functions. Vasculogenesis and angiogenesis might contribute to the MM vascular tree and progression, in the form of growth, invasion, and dissemination. In view of the heterogeneity of the antigenic phenotype of MMECs, a mixture (or a sequence) of antiangiogenic agents coupled with thalidomide would seem plausible for the biologic management of MM.",
author = "Angelo Vacca and Roberto Ria and Fabrizio Semeraro and Francesca Merchionne and Mauro Coluccia and Angela Boccarelli and Claudio Scavelli and Beatrice Nico and Angela Gernone and Feliciana Battelli and Antonio Tabilio and Diego Guidolin and Petrucci, {Maria Teresa} and Domenico Ribatti and Franco Dammacco",
year = "2003",
month = "11",
day = "1",
doi = "10.1182/blood-2003-04-1338",
language = "English",
volume = "102",
pages = "3340--3348",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Endothelial cells in the bone marrow of patients with multiple myeloma

AU - Vacca, Angelo

AU - Ria, Roberto

AU - Semeraro, Fabrizio

AU - Merchionne, Francesca

AU - Coluccia, Mauro

AU - Boccarelli, Angela

AU - Scavelli, Claudio

AU - Nico, Beatrice

AU - Gernone, Angela

AU - Battelli, Feliciana

AU - Tabilio, Antonio

AU - Guidolin, Diego

AU - Petrucci, Maria Teresa

AU - Ribatti, Domenico

AU - Dammacco, Franco

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Endothelial cells (EC) were extracted through a lectin-based method from bone marrow of 57 patients with active multiple myeloma (MM) and compared with their healthy quiescent counterpart, human umbilical vein EC (HUVEC). MMECs exhibit specific antigens that indicate ongoing angiogenesis and embryo vasculogenesis; solid intercellular connections, hence stability of MM neovessels; and frequent interactions with plasma cells, hence tumor dissemination. They show heterogeneous antigen expression, hence existence of subsets. Their main genetic markers are indicative of a vascular phase. They show intrinsic angiogenic ability, because they rapidly form a capillary network in vitro, and extrinsic ability, because they generate numerous new vessels in vivo. They vividly secrete growth and invasive factors for plasma cells. They signal through kinases mandatory for development of neovascularization. Ultrastructurally, they are abnormal and show metabolic activation, like tumor ECs. Thalidomide heavily interferes with their functions. Vasculogenesis and angiogenesis might contribute to the MM vascular tree and progression, in the form of growth, invasion, and dissemination. In view of the heterogeneity of the antigenic phenotype of MMECs, a mixture (or a sequence) of antiangiogenic agents coupled with thalidomide would seem plausible for the biologic management of MM.

AB - Endothelial cells (EC) were extracted through a lectin-based method from bone marrow of 57 patients with active multiple myeloma (MM) and compared with their healthy quiescent counterpart, human umbilical vein EC (HUVEC). MMECs exhibit specific antigens that indicate ongoing angiogenesis and embryo vasculogenesis; solid intercellular connections, hence stability of MM neovessels; and frequent interactions with plasma cells, hence tumor dissemination. They show heterogeneous antigen expression, hence existence of subsets. Their main genetic markers are indicative of a vascular phase. They show intrinsic angiogenic ability, because they rapidly form a capillary network in vitro, and extrinsic ability, because they generate numerous new vessels in vivo. They vividly secrete growth and invasive factors for plasma cells. They signal through kinases mandatory for development of neovascularization. Ultrastructurally, they are abnormal and show metabolic activation, like tumor ECs. Thalidomide heavily interferes with their functions. Vasculogenesis and angiogenesis might contribute to the MM vascular tree and progression, in the form of growth, invasion, and dissemination. In view of the heterogeneity of the antigenic phenotype of MMECs, a mixture (or a sequence) of antiangiogenic agents coupled with thalidomide would seem plausible for the biologic management of MM.

UR - http://www.scopus.com/inward/record.url?scp=0142183449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142183449&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-04-1338

DO - 10.1182/blood-2003-04-1338

M3 - Article

C2 - 12855563

AN - SCOPUS:0142183449

VL - 102

SP - 3340

EP - 3348

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -